Evidence map›Paper›PMID 19058312›Full record

ArticleWorld journal of gastroenterology2008

Induction of IgA and sustained deficiency of cell proliferative response in chronic hepatitis C.

Yalena Amador-Cañizares, Liz Alvarez-Lajonchere, Ivis Guerra, Ingrid Rodríguez-Alonso, Gillian Martínez-Donato, Julián Triana, Eddy E González-Horta, Angel Pérez, Santiago Dueñas-Carrera

Open access · greenAbstract read
In one paragraph

Article in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yalena Amador-CañizaresHCV Department, Vaccine Division, Centro de Ingeniería Genética y Biotecnología, Ave 31, 58 and 190, Playa, P.O. Box 6162, Havana, Cuba. yalena.amador@cigb.edu.cu
Liz Alvarez-Lajonchere
Ivis Guerra
Ingrid Rodríguez-Alonso
Gillian Martínez-Donato
Julián Triana
Eddy E González-Horta
Angel Pérez
Santiago Dueñas-Carrera
Centro de Ingeniería Genética y Biotecnología · CU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimIn the present study, antibody and peripheral blood mononuclear cells (PBMC) proliferative responses against hepatitis C virus (HCV) antigens were evaluated in HCV chronically infected patients.

methodsPaired serum and PBMC samples were taken six months apart from 34 individuals, either treated or not, and tested by enzyme-linked immunosorbent assay (ELISA) and carboxyfluorescein succinimidyl ester staining.

resultsOver 70% of the patients showed specific IgG and IgM against capsid, E1 and NS3, while HVR-1 was recognized by half of the patients. An increase in the levels of the anti-capsid IgM (P = 0.027) and IgG (P = 0.0006) was observed in six-month samples, compared to baseline. Similarly, a significantly higher percent of patients had detectable IgA reactivity to capsid (P = 0.017) and NS3 (P = 0.005) after six months, compared to baseline. Particularly, IgA against structural antigens positively correlated with hepatic damage (P = 0.036). IgG subclasses evaluation against capsid and NS3 revealed a positive recognition mediated by IgG1 in more than 80% of the individuals. On the contrary, less than 30% of the patients showed a positive proliferative response either of CD4+ or CD8+ T cells, being the capsid poorly recognized.

conclusionThese results confirm that while the cellular immune response is narrow and weak, a broad and vigorous humoral response occurs in HCV chronic infection. The observed correlation between IgA and hepatic damage may have diagnostic significance, although it warrants further confirmation.

Indexed as

Cell ProliferationAdultAntibody FormationAntiviral AgentsCapsid ProteinsDEAD-box RNA HelicasesFemaleHepacivirusHepatitis C AntibodiesHepatitis C AntigensHepatitis C, ChronicHumansImmunoglobulin AInterferon-alphaLeukocytes, MononuclearLymphocyte ActivationAntiviral AgentsCapsid ProteinsDEAD-box RNA HelicasesE1 protein, Hepatitis C virusHepatitis C AntibodiesHepatitis C AntigensImmunoglobulin AInterferon-alphaNS3 protein, hepatitis C virusNucleoside-TriphosphataseRibavirinSerine EndopeptidasesViral Envelope ProteinsViral Nonstructural ProteinsViral Proteases

Identifiers

PMID19058312
PMCPMC2773881
OpenAlexW2066748805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.